Zhu, Bo

Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel

Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 471

Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages

Chen, D., Zhang, X., Li, Z., & Zhu, B. (2021) · Theranostics

Immune cells in cancerCancer, Hypoxia, and Metabolism

Cited by 390

EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells

Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B. (2019) · Cancer Research

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 185

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 152

Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy

Gao, J., Zhao, L., Wan, Y., & Zhu, B. (2015) · International Journal of Molecular Sciences

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 122

An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy

Chen, X., Zhao, J., Yue, S., Li, Z., Duan, X., Lin, Y., Yang, Y., He, J., Gao, L., Pan, Z., et al. (2024) · Nature Cancer

Immunotherapy and Immune ResponsesVirus-based gene therapy research

Cited by 68

CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis

Hu, X., Zhao, Y., Wei, L., Zhu, B., Song, D., Wang, J., Yu, L., & Wu, J. (2017) · Oncogene

Hepatocellular Carcinoma Treatment and PrognosisMechanisms of cancer metastasis

Cited by 54

Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma

Gong, Z., Jia, Q., Chen, J., Diao, X., Gao, J., Wang, X., & Zhu, B. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 43

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

Shi, Y., Zhao, Y., Yang, S., Zhou, J., Zhang, L., Chen, G., Fang, J., Zhu, B., Li, X., Shu, Y., et al. (2022) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 27

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Shi, Y., Zhou, J., Zhao, Y., Zhu, B., Zhang, L., Li, X., Fang, J., Shi, J., Zhuang, Z., Yang, S., et al. (2023) · BMC Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 13